|
1
|
Lavanchy D: The global burden of Hepatitis
C. Liver Int. 29 (Suppl 1):S74–S81. 2009. View Article : Google Scholar
|
|
2
|
Axley P, Ahmed Z, Ravi S and Singal AK:
Hepatitis C virus and hepatocellular carcinoma: A narrative review.
J Clin Transl Hepatol. 6:79–84. 2018.PubMed/NCBI
|
|
3
|
Pawlotsky JM: New Hepatitis C therapies:
The toolbox, strategies, and challenges. Gastroenterology.
146:1176–1192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crouchet E, Wrensch F, Schuster C, Zeisel
MB and Baumert TF: Host-targeting therapies for Hepatitis C virus
infection: Current developments and future applications. Therap Adv
Gastroenterol. 11:17562848187594832018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Averhoff FM, Glass N and Holtzman D:
Global burden of Hepatitis C: Considerations for healthcare
providers in the United States. Clin Infect Dis. 55 (Suppl
1):S10–S15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dhingra A, Kapoor S and Alqahtani SA:
Recent advances in the treatment of Hepatitis C. Discov Med.
18:203–208. 2014.PubMed/NCBI
|
|
7
|
Zignego AL, Ferri C, Pileri SA, Caini P
and Bianchi FB; Italian Association of the study of liver
commission on Extrahepatic manifestations of HCV infection, :
Extrahepatic manifestations of Hepatitis C Virus infection: A
general overview and guidelines for a clinical approach. Dig Liver
Dis. 39:2–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cacoub P, Gragnani L, Comarmond C and
Zignego AL: Extrahepatic manifestations of chronic Hepatitis C
virus infection. Dig Liver Dis. 46 (Suppl 5):S165–S173. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
White DL, Ratziu V and El-Serag HB:
Hepatitis C infection and risk of diabetes: A systematic review and
meta-analysis. J Hepatol. 49:831–844. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nadolnik K, Skrypnik D, Skrypnik K and
Bogdański P: Diabetic nephropathy in the elderly-clinical practice.
Rocz Panstw Zakl Hig. 69:327–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moucari R, Asselah T, Cazals-Hatem D,
Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M,
Maylin S, Nicolas-Chanoine MH, et al: Insulin resistance in chronic
Hepatitis C: Association with genotypes 1 and 4, serum HCV RNA
level, and liver fibrosis. Gastroenterology. 134:416–423. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang CS, Wang ST, Yao WJ, Chang TT and
Chou P: Hepatitis C virus infection and the development of type 2
diabetes in a community-based longitudinal study. Am J Epidemiol.
166:196–203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kralj D, Virović Jukić L, Stojsavljević S,
Duvnjak M, Smolić M and Čurčić IB: Hepatitis C virus, insulin
resistance, and steatosis. J Clin Transl Hepatol. 4:66–75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El-Zayadi AR and Anis M: Hepatitis C virus
induced insulin resistance impairs response to anti viral therapy.
World J Gastroenterol. 18:212–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petta S, Cammà C, Di Marco V, Alessi N,
Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G,
Marchesini G and Craxì A: Insulin resistance and diabetes increase
fibrosis in the liver of patients with genotype 1 HCV infection. Am
J Gastroenterol. 103:1136–1144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deltenre P, Louvet A, Lemoine M, Mourad A,
Fartoux L, Moreno C, Henrion J, Mathurin P and Serfaty L: Impact of
insulin resistance on sustained response in HCV patients treated
with pegylated interferon and ribavirin: A meta-analysis. J
Hepatol. 55:1187–1194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo X, Jin M, Yang M, Liu K and Li JW:
Type 2 diabetes mellitus and the risk of hepatitis C virus
infection: A systematic review. Sci Rep. 3:29812013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sheikh MY, Choi J, Qadri I, Friedman JE
and Sanyal AJ: Hepatitis C virus infection: Molecular pathways to
metabolic syndrome. Hepatology. 47:2127–2133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aghemo A, Prati GM, Rumi MG, Soffredini R,
D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V and
Colombo M: Sustained virological response prevents the development
of insulin resistance in patients with chronic hepatitis C.
Hepatology. 56:1681–1687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawaguchi T, Ide T, Taniguchi E, Hirano E,
Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H and Sata
M: Clearance of HCV improves insulin resistance, beta-cell
function, and hepatic expression of insulin receptor substrate 1
and 2. Am J Gastroenterol. 102:570–576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawaguchi Y and Mizuta T: Interaction
between hepatitis C virus and metabolic factors. World J
Gastroenterol. 20:2888–2901. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim HJ, Park JH, Park DI, Cho YK, Sohn CI,
Jeon WK and Kim BI: Clearance of HCV by combination therapy of
pegylated interferon alpha-2a and ribavirin improves insulin
resistance. Gut Liver. 3:108–115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Delgado-Borrego A, Jordan SH, Negre B,
Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS and
Chung RT; Halt-C Trial Group, : Reduction of insulin resistance
with effective clearance of hepatitis C infection: Results from the
HALT-C trial. Clin Gastroenterol Hepatol. 8:458–462. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eslam M, Aparcero R, Kawaguchi T, Del
Campo JA, Sata M, Khattab MA and Romero-Gomez M: Meta-analysis:
Insulin resistance and sustained virological response in hepatitis
C. Aliment Pharmacol Ther. 34:297–305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thompson AJ, Patel K, Chuang WL, Lawitz
EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M,
Arora S, et al: Viral clearance is associated with improved insulin
resistance in genotype 1 chronic hepatitis C but not genotype 2/3.
Gut. 61:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petta S, Cammà C, Di Marco V, Cabibi D,
Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G and
Craxì A: Time course of insulin resistance during antiviral therapy
in non-diabetic, non-cirrhotic patients with genotype 1 HCV
infection. Antivir Ther. 14:631–639. 2009.PubMed/NCBI
|
|
27
|
Cacoub P, Desbois AC, Comarmond C and
Saadoun D: Impact of sustained virological response on the
extrahepatic manifestations of chronic hepatitis C: A
meta-analysis. Gut. 67:2025–2034. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ciancio A, Bosio R, Bo S, Pellegrini M,
Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld AGF, Gallo
M, Giordanino C, et al: Significant improvement of glycemic control
in diabetic patients with HCV infection responding to direct-acting
antiviral agents. J Med Virol. 90:320–327. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate health care
interventions: Explanation and elaboration. J Clin Epidemiol.
62:e1–e34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sterne JA, Sutton AJ, Ioannidis JP, Terrin
N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH,
et al: Recommendations for examining and interpreting funnel plot
asymmetry in meta-analyses of randomised controlled trials. BMJ.
343:d40022011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hayden JA, van der Windt DA, Cartwright
JL, Côté P and Bombardier C: Assessing bias in studies of
prognostic factors. Ann Intern Med. 158:280–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW,
Jang JY, Lee SH, Kim HS and Kim BS: The impact of pegylated
interferon and ribavirin combination treatment on lipid metabolism
and insulin resistance in chronic hepatitis C patients. Clin Mol
Hepatol. 20:38–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chan CH, Hansen RD, Gilliver RS and Jones
BE: Sustained virological response following chronic hepatitis C
treatment is associated with improvement in insulin resistance.
Intern Med J. 43:656–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khattab MA, Eslam M, Shatat M,
Abd-Aalhalim H, Mousa YI, Samir F, Aly H, Shaker O and Shaker Y:
Changes in adipocytokines and insulin sensitivity during and after
antiviral therapy for hepatitis C genotype 4. J Gastrointestin
Liver Dis. 21:59–65. 2012.PubMed/NCBI
|
|
35
|
Kawaguchi Y, Mizuta T, Oza N, Takahashi H,
Ario K, Yoshimura T, Eguchi Y, Ozaki I, Hisatomi A and Fujimoto K:
Eradication of hepatitis C virus by interferon improves whole-body
insulin resistance and hyperinsulinaemia in patients with chronic
hepatitis C. Liver Int. 29:871–877. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Laurito MP and Parise ER: Association
between insulin resistance and sustained virologic response in
hepatitis C treatment, genotypes 1 versus 2 and 3: Systematic
literature review and meta-analysis. Braz J Infect Dis. 17:555–563.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fried MW, Jensen DM, Rodriguez-Torres M,
Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli
L, Duff F, et al: Improved outcomes in patients with hepatitis C
with difficult-to-treat characteristics: Randomized study of higher
doses of peginterferon alpha-2a and ribavirin. Hepatology.
48:1033–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang ML, Kuo CJ, Pao LH, Hsu CM and Chiu
CT: The evolving relationship between adiponectin and insulin
sensitivity in hepatitis C patients during viral clearance.
Virulence. 8:1255–1264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang ML: Metabolic alterations and
hepatitis C: From bench to bedside. World J Gastroenterol.
22:1461–1476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miczke A, Suliburska J, Pupek-Musialik D,
Ostrowska L, Jabłecka A, Krejpcio Z, Skrypnik D and Bogdański P:
Effect of L-arginine supplementation on insulin resistance and
serum adiponectin concentration in rats with fat diet. Int J Clin
Exp Med. 8:10358–10366. 2015.PubMed/NCBI
|
|
41
|
Kujawska-Luczak M, Szulinska M, Skrypnik
D, Musialik K, Swora-Cwynar E, Kregielska-Narozna M, Markuszewski
L, Grzymislawska M and Bogdanski P: The influence of orlistat,
metformin and diet on serum levels of insulin-like growth factor-1
in obese women with and without insulin resistance. J Physiol
Pharmacol. 69:2018.
|
